Skip to content
Independent analysis of NHS open data
PharmaInsight

Sevoflurane 100% inhalation vapour liquid

Secondary Care Medicines Data (SCMD) · indicative cost
Data updated April 2026

NHS hospitals in England used £23,652,752 of indicative cost of Sevoflurane 100% inhalation vapour liquid in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is down 2.4% on the previous 12 months.

£23,652,752 -2.4%

Indicative cost · 12 months

48,074,699units

Quantity (VMP units) · 12 months

0.1%

Share of hospital medicines spend

Figure 1. Sevoflurane 100% inhalation vapour liquid: NHS hospital indicative cost by month (£ millions)

£0m £1.1m £2.3m Oct 2024 Jan 2025 Apr 2025 Jul 2025 Oct 2025 Jan 2026 Apr 2026 £1.9m Oct 2024: £2.3m Nov 2024: £2m Dec 2024: £1.9m Jan 2025: £2.0m Feb 2025: £1.9m Mar 2025: £2.1m Apr 2025: £2m May 2025: £2.0m Jun 2025: £2m Jul 2025: £2.1m Aug 2025: £1.8m Sep 2025: £2.1m Oct 2025: £2.1m Nov 2025: £1.9m Dec 2025: £1.9m Jan 2026: £1.8m Feb 2026: £1.8m Mar 2026: £2.2m Apr 2026: £1.9m

Source: NHSBSA Secondary Care Medicines Data, to April 2026

Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.

NHS trusts using Sevoflurane 100% inhalation vapour liquid most

By indicative cost over the 12 months to April 2026.

NHS trusts using Sevoflurane 100% inhalation vapour liquid most, by indicative cost
NHS trustIndicative cost (12 months)
Leeds Teaching Hpls Nhs Trust £690,153
Univ Hpl B/Ham Nhs Foundation Trust £626,931
Barts Health Nhs Trust £564,816
Manchester University Nhs Ft £471,951
The Newcastle Upon Tyne Hpl Nhs Found Tr £448,704
Guy's & St Thomas' Nhs Foundation Trust £424,842
University Hpls Of Leicester Nhs Trust £410,820
King's College Hpl Nhs Foundation Trust £388,557
Southend Univ Hosp Nhs Foundation Trust £382,161
University Hpls North Midlands Nhs Trust £377,856

The primary-care picture

No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.